Literature DB >> 2787359

IFN-beta 2/IL-6 augments the activity of human natural killer cells.

T A Luger1, J Krutmann, R Kirnbauer, A Urbanski, T Schwarz, G Klappacher, A Köck, M Micksche, J Malejczyk, E Schauer.   

Abstract

MHC nonrestricted cytotoxic cells play an important role in the killing of tumor cells in vitro and potentially in vivo. The activity of these cells is regulated by several cytokines such as IL-2 and IFN. In the present study we provide first evidence that IL-6 significantly augments the cytotoxic activity of human NK cells. IL-6 is produced by many different cells and is also known as IFN-beta 2, B cell stimulatory factor 2, hybridoma growth factor, hepatocyte-stimulating factor, and 26 kDa protein. IL-6 stimulates the activity of human CD3- NK cells but not that of CD3+ non-MHC-restricted cytotoxic T lymphocytes. As is the case with IL-2, the IL-6-mediated augmented cytotoxicity was a result of a more efficient lysis, but was not caused by an increased effector to target cell binding. Moreover, the effect of IL-6 on NK cell activity was blocked by a mAb directed against IL-2, and IL-6 itself was found to be a potent inducer of IL-2 production in cultured human PBMC. Thus it may be concluded that IL-6 enhances the cytotoxic activity of NK cells via IL-2. This newly recognized property of IL-6, which is produced by almost any cell, may be of importance in host defense against microbes and malignancies and therefore could contribute to improve the adoptive immunotherapy by using lymphokine-activated killer cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787359

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

Review 1.  Interleukin 12 and innate molecules for enhanced mucosal immunity.

Authors:  P N Boyaka; J W Lillard; J McGhee
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Subpopulations of mononuclear leukocytes associated with inhibition of Ehrlich ascites tumor growth by treatment with Bothrops jararaca venom.

Authors:  Mariana Morena de Vieira Santos; Reinaldo José da Silva; Márcia Guimarães da Silva; Denise Fecchio
Journal:  Mediators Inflamm       Date:  2004-02       Impact factor: 4.711

3.  Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.

Authors:  J Tanner; G Tosato
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 4.  Cardiac biomarkers: new tools for heart failure management.

Authors:  Navaid Iqbal; Bailey Wentworth; Rajiv Choudhary; Alejandro De La Parra Landa; Benjamin Kipper; Arrash Fard; Alan S Maisel
Journal:  Cardiovasc Diagn Ther       Date:  2012-06

5.  T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

Authors:  Florian Anzengruber; Pinar Avci; Lucas Freitas de Freitas; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-06-11       Impact factor: 3.982

6.  Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease.

Authors:  C Stevens; G Walz; C Singaram; M L Lipman; B Zanker; A Muggia; D Antonioli; M A Peppercorn; T B Strom
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

7.  Interleukin-6 and acute-phase proteins in head and neck cancer.

Authors:  O Gallo; A M Gori; M Attanasio; F Martini; B Giusti; T Brunelli; E Gallina
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

8.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

9.  Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice.

Authors:  B Ryffel; B D Car; H Gunn; D Roman; P Hiestand; M J Mihatsch
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

Review 10.  Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense.

Authors:  L Graeve; M Baumann; P C Heinrich
Journal:  Clin Investig       Date:  1993-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.